CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 229 enrolled
Drug / intervention
simvastatin (+) ezetimibe +1 moredrug
Likely dose
simvastatin (+) ezetimibe 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00442897
NCT00442897Phase 4Completed
CompareCT.gov

Evaluate The Lipid-Lowering Efficacy and Safety of Vytorin in Comparison With Atorvastatin in Hypercholesterolaemic Patients With Coronary Artery Disease

Organon and Co·interventional·Posted Mar 5, 2007·Updated May 22, 2024

In Brief

A Phase 4 clinical trial evaluating simvastatin (+) ezetimibe and Comparator: atorvastatin for Hypercholesterolemia. Completed, enrolled 229 participants.

Detailed Summary

Evaluate the proportion of hyperlipaemic persons with known coronary heart disease achieving ldl-c goal as defined by the national cholesterol education program (NCEP) adult treatment panel (ATP) III guidelines

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 5, 2007
Enrollment StartSep 1, 2006
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.3 years ago

Interventions

simvastatin (+) ezetimibedrug

simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)

Comparator: atorvastatindrug

atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)